[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100407642":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":42,"centralContacts":46,"locations":56,"responsibleParty":74,"collaborators":51,"id":76,"slug":51,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":51,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":51,"enrollmentInfo":84,"targetDuration":51,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":58,"whyStopped":51,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Mercy Medical Center","OTHER",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Cirrhosis, 3-dose regimen","EXPERIMENTAL","Investigators will randomize the patient in the cirrhotic group to receive a 3-dose regimen of Heplisav-B.",[13],"Biological: Heplisav-B Injectable Product, 3-dose regimen",{"label":15,"type":16,"description":17,"interventionNames":18},"Cirrhosis, 2-dose regimen","ACTIVE_COMPARATOR","Investigators will randomize the patient in the cirrhotic group to receive a 2-dose regimen of Heplisav-B.",[19],"Biological: Heplisav-B Injectable Product, 2-dose regimen",{"label":21,"type":10,"description":22,"interventionNames":23},"Non cirrhosis, 3-dose regimen","Investigators will randomize the patient in the noncirrhotic group to receive a 3-dose regimen of Heplisav-B.",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Non cirrhosis, 2-dose regimen","Investigators will randomize the patient in the noncirrhotic group to receive a 2-dose regimen of Heplisav-B.",[19],[29,36],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"BIOLOGICAL","Heplisav-B Injectable Product, 2-dose regimen","Investigators will randomly assign patients into a 2-dose regimen.",[15,25],[35],"2-dose regimen",{"type":30,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Heplisav-B Injectable Product, 3-dose regimen","Investigators will randomly assign patients into a 3-dose regimen.",[9,21],[41],"3-dose regimen",[43],{"name":44,"affiliation":5,"role":45},"Paul Thuluvath, MD","PRINCIPAL_INVESTIGATOR",[47,53],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},"CHAU TO, MD","CONTACT","(714)-400-1331",null,"cto@mdmercy.com",{"name":44,"role":49,"phone":54,"phoneExt":51,"email":55},"(410)-332-9308","pthuluv@mdmercy.com",[57],{"facility":5,"status":58,"city":59,"state":60,"zip":61,"country":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"RECRUITING","Baltimore","Maryland","21202","United States",{"type":64,"coordinates":65},"Point",[66,67],-76.61219,39.29038,{"lat":67,"lon":66},[70,72],{"name":48,"role":49,"phone":71,"phoneExt":51,"email":52},"714-400-1331",{"name":73,"role":49,"phone":54,"phoneExt":51,"email":55},"PAUL THULUVATH, MD",{"type":75,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR","100407642",false,"NCT04588077","Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis","Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.","Inclusion Criteria:\n\n\\- All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09\u002F2020 and 07\u002F2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer \\\u003C 10 mIU\u002Fml) will be recruited.\n\nExclusion Criteria:\n\n* Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine.\n* Those who had previous exposure to hepatitis B.\n* Post liver transplant patients.\n* Less than 18 years old.","ALL","18 Years",{"count":85,"type":86},200,"ESTIMATED","INTERVENTIONAL",[89],"PHASE4","Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.",[92,93,94],"Hepatitis B","Cirrhosis, Liver","Chronic Liver Disease",[96,97,98,99,100,101,102,103,104],"hepatitis B vaccine","Heplisav-B","cirrhosis","chronic liver disease","2 dose regimen","3 dose regimen","non responder","poor responder","no response","2024-11-18",{"date":107,"type":108},"2024-11-19","ACTUAL",{"date":110,"type":108},"2020-09-14",{"date":112,"type":86},"2028-12-01",{"name":5,"class":6},1]